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Systemic insulin resistance produces a proatherogenic lipid phenotype. Early in the course of systemic insulin resistance, FFAs increase because 
of loss of the suppressive effects of insulin on lipolysis in adipocytes. Fatty acids are transported to the liver, where the availability of lipid stabilizes 
the production of apoB, the major apolipoprotein of VLDL particles. Decreased insulin signaling dampens degradative pathways for apoB, which 
also contributes to increased VLDL production. Lipoprotein lipase, found in the endothelium of peripheral capillaries and rate-limiting for the clear-
ance of triglyceride-rich lipoproteins, is decreased in insulin resistance. Hence, hypertriglyceridemia in insulin resistance (reflecting elevated VLDL 
particles) occurs because of a combination of increased VLDL production and decreased VLDL clearance. VLDLs are metabolized to remnant 
lipoproteins, which can promote atheroma formation. The presence of increased VLDL particles also affects HDL metabolism. Triglycerides in 
VLDL are transferred to HDL through the action of cholesteryl ester transfer protein (CETP). This process results in a triglyceride-enriched HDL 
particle that is more rapidly cleared from the circulation, leaving fewer HDL particles to accept cholesterol from the vasculature.
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Summary of beneficial interventions in insulin resistance
Study	 Subjects	 Treatment	 Major	outcomes
Statin	use	in	insulin	resistance
Heart Protection Study Type 2 diabetes  Simvastatin  Decrease in vascular events for entire cohort, subset with diabetes,  
 or vascular disease versus placebo  and those with diabetes and low LDL; decrease in total mortality  
    for entire group
CARDS Type 2 diabetes  Atorvastatin  Decrease in vascular events; nearly significant decrease in total  
 and no known versus placebo  mortality(P = 0.059) 
 vascular disease
LIPID trial Known vascular  Pravastatin  Decrease in vascular events and total mortality for entire cohort;  
 disease versus placebo  decrease in vascular events for subset with impaired fasting glucose
Interruption	of	renin-angiotensin	system	in	insulin	resistance	 	 	
HOPE trial Vascular disease  Ramipril  Decrease in vascular events and total mortality for entire cohort;  
 or diabetes versus placebo  decrease in vascular events in subset with diabetes; decrease in  
    new-onset diabetes
LIFE trial Diabetes and  Losartan  Fewer vascular events and lower total mortality in losartan group 
 hypertension versus atenolol
CARDS, Collaborative Atorvastatin Diabetes Study; LIPID, Long-Term Intervention with Pravastatin in Ischemic Disease; HOPE, Heart Outcomes Preven-
tion Evaluation; LIFE, Losartan Intervention for Endpoint Reduction in Hypertension.
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Summary of trials using PPAR activation
Study	 Agonist	 Major	outcomes
PPARα	agonists	 	
WHO cooperative trial Clofibrate Decrease in coronary events in this primary prevention trial; no effect on vascular disease death;  
   increase in total mortality (P < 0.01)
Helsinki Heart Study Gemfibrozil Decrease in vascular events and vascular death in this primary prevention trial; no effect on total  
   mortality (rate [per 1,000]: 21.9 for gemfibrozil, 20.7 for placebo)
VA-HIT Gemfibrozil Decrease in vascular events in this secondary prevention trial; nearly significant decrease in vascular  
   death (P = 0.07); no effect on total mortality (9.9% deaths for gemfibrozil, 10.9% deaths for placebo)
BIP study Bezafibrate No effect on vascular events; apparent benefit in post hoc analysis of subset of patients with  
   triglycerides over 200 mg/dl; no effect on total mortality (10.4% deaths for bezafibrate,  
   9.9% deaths for placebo)
FIELD study Fenofibrate No effect on primary endpoint of coronary events; decreased secondary endpoint of total  
   cardiovascular events (P = 0.035); nonsignificant increase in coronary heart disease mortality  
   and total mortality (rate: 14.2 for fenofibrate, 12.9 for placebo)
PPARγ	agonist	 	
PROACTIVE Pioglitazone No effect on primary endpoint of all vascular events in this secondary prevention trial; decreased  
   secondary endpoint of death, nonfatal myocardial infarction, CVA (P = 0.027); no effect on total  
   mortality with fewer overall deaths in pioglitazone group
VA-HIT, Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial; BIP, Bezafibrate Infarction Prevention; FIELD, Fenofibrate Intervention 
and Event Lowering in Diabetes; PROACTIVE, Prospective Pioglitazone Clinical Trial in Macrovascular Events.
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Nutrient excess, organelle stress, and the 
development of atherosclerosis and insulin 
resistance. The excess delivery of glucose, 
lipids, and other nutrients disrupts homeo-
stasis at key organelles, leading to genomic 
and ER stress. Increased fuel flow is associ-
ated with increased mitochondrial metabolism 
with the potential for excessive generation of 
reactive oxygen species, leading to mitochon-
drial dysfunction. The nuclear genome may 
be affected by oxidative modifications and by 
structural alterations due to the accumulation 
of intracellular lipids, both of which may disrupt 
repair mechanisms as well as transcriptional 
responses that minimize inflammatory dam-
age. Excessive demand on the ER induces 
stress responses that lead to inflammation. 
Genomic and ER stress could be adaptive in 
the short term, since decreased insulin signal-
ing would limit additional uptake of nutrients 
and increased macrophage activation would 
clear toxic lipids. However, these independent 
processes stimulated by organelle stress ulti-
mately become maladaptive in the setting of 
continued nutrient excess.
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DNA damage disorders associated with insulin resistance and atherosclerosis
Syndrome	 Molecular	defect		 Phenotype
Hutchinson-Gilford progeria De novo point mutation in lamin A  Atherosclerosis, insulin resistance, hyperglycemia, growth retardation,  
 gene resulting in truncated protein  lipodystrophy, osteoporosis, hair and skin abnormalities
Werner  Mutation in WRN, a DNA helicase Atherosclerosis, malignancies, insulin resistance, central adiposity,  
   dyslipidemia, autoimmunity, osteoporosis
Ataxia telangiectasia Defect in ATM, a protein kinase  Cerebellar ataxia, skin and eye telangiectasias, malignancies, immune  
 with p53 as a substrate  deficiency, impaired growth, insulin resistance, atherosclerosis  
   in heterozygotes
Cockayne Mutations in CSA and CSB,  Neurodegeneration, ataxia and mental retardation, atherosclerosis,  
 involved in DNA repair  insulin resistance, dyslipidemia, impaired growth
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